Skip to content

Lysosomal Acid Lipase (LAL) Deficiency Registry

Lysosomal Acid Lipase Deficiency | Wolman Disease | Acid Lipase Deficiency | Cholesterol Ester Storage...

This is an observational, multi-center, international disease registry designed to collect longitudinal data and create a knowledge base that will be utilized to improve the care and treatment of patients with LAL Deficiency. Participation in the Registry by both physicians and patients is voluntary.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    0 and up

Critères de participation

Patients must have a confirmed diagnosis of LAL Deficiency. An Informed Consent and Authorization must be obtained prior to patient enrollment where required under applicable laws and regulations, or a waiver must be obtained by the Institutional Review Board/Independent Ethics Committee.

Patients cannot be currently participating in an Alexion-sponsored clinical trial. Patients who have concluded participation in an Alexion-sponsored sebelipase alfa clinical trial are eligible to enroll in this Registry, and enrollment in the Registry will not exclude a patient from enrolling in a future clinical trial.

Lieu de l'étude


London, Ontario
Canada

Contactez l'équipe d'étude

Étude parrainée par
Alexion Pharmaceuticals, Inc.
Participants recherchés
Plus d'informations
ID de l'étude: NCT01633489